To the best of our knowledge, these advantages set the LALUCA registry apart from other international registries such as the Danish lung cancer registry, which cannot provide information on curative or palliative treatment intent or specify oncological treatment, or the National Lung Cancer Audit UK, which only requires EGFR mutation status, ALK and ROS1 fusion status and PD-L1 expression for minimal completion of a patient thereby limiting detailed information on molecular biomarkers in their overall dataset [21–23]. This evidence concerns the gene EGFR and lung carcinoma.